Edition:
United States

Fibrocell Science Inc (FCSC.OQ)

FCSC.OQ on NASDAQ Stock Exchange Capital Market

2.34USD
20 Jul 2018
Change (% chg)

$0.07 (+3.08%)
Prev Close
$2.27
Open
$2.28
Day's High
$2.34
Day's Low
$2.23
Volume
8,308
Avg. Vol
65,486
52-wk High
$19.55
52-wk Low
$2.15

Chart for

About

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $12.94
Shares Outstanding(Mil.): 5.68
Dividend: --
Yield (%): --

Financials

  FCSC.OQ Industry Sector
P/E (TTM): -- 214.53 33.05
EPS (TTM): -4.73 -- --
ROI: -88.37 -3.67 13.17
ROE: -178.69 -5.61 15.10

BRIEF-Fibrocell Reports On Interim Results And Progress Of Phase 1/2 Clinical Trial Of FCX-007 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

* FIBROCELL REPORTS ON INTERIM RESULTS AND PROGRESS OF PHASE 1/2 CLINICAL TRIAL OF FCX-007 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA

May 21 2018

BRIEF-Fibrocell Reports Q1 Loss Per Share $0.11

* FIBROCELL REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

May 10 2018

BRIEF-Fibrocell Announces Review Of Strategic Alternatives

* FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS

Apr 18 2018

BRIEF-Fibrocell Reports 2017 Financial Results And Recent Highlights

* FIBROCELL REPORTS 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS Source text for Eikon: Further company coverage:

Mar 19 2018

BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013

* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA

Mar 06 2018

BRIEF-Fibrocell Science Says‍ Expect To Initiate A Safety Clinical Trial In 2018 For Fcx-013 Development

* FIBROCELL SCIENCE SAYS‍ EXPECT TO INITIATE A SAFETY CLINICAL TRIAL IN 2018 FOR FCX-013 DEVELOPMENT - SEC FILING​ Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Fibrocell Science Says Submitted IND Application For FCX-013 To Treat Type Of Skin Disorder

* FIBROCELL SCIENCE SAYS SUBMITTED INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA​ Source text for Eikon: Further company coverage:

Feb 05 2018

BRIEF-Fibrocell Announces FDA Allowance To Initiate Pediatric Enrollment In Phase 1/2 Clinical Trial Of Fcx-007

* FIBROCELL ANNOUNCES FDA ALLOWANCE TO INITIATE PEDIATRIC ENROLLMENT IN PHASE 1/2 CLINICAL TRIAL OF FCX-007 FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)

Jan 30 2018

Earnings vs. Estimates